vs

Side-by-side financial comparison of Connect Biopharma Holdings Ltd (CNTB) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.

Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $24.1M, roughly 1.3× Connect Biopharma Holdings Ltd). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs 36.3%, a 25.3% gap on every dollar of revenue.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.

CNTB vs PDLB — Head-to-Head

Bigger by revenue
PDLB
PDLB
1.3× larger
PDLB
$31.4M
$24.1M
CNTB
Higher net margin
CNTB
CNTB
25.3% more per $
CNTB
61.6%
36.3%
PDLB

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CNTB
CNTB
PDLB
PDLB
Revenue
$24.1M
$31.4M
Net Profit
$14.8M
$10.1M
Gross Margin
Operating Margin
56.6%
43.6%
Net Margin
61.6%
36.3%
Revenue YoY
37.6%
Net Profit YoY
148.7%
245.6%
EPS (diluted)
$0.27
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNTB
CNTB
PDLB
PDLB
Q4 25
$31.4M
Q3 25
$26.7M
Q2 25
$26.5M
Q1 25
$24.6M
Q4 24
$22.8M
Q3 24
$20.2M
Q2 24
$24.1M
$20.2M
Q1 24
$20.5M
Net Profit
CNTB
CNTB
PDLB
PDLB
Q4 25
$10.1M
Q3 25
$6.5M
Q2 25
$6.1M
Q1 25
$6.0M
Q4 24
$2.9M
Q3 24
$2.4M
Q2 24
$14.8M
$3.2M
Q1 24
$2.4M
Operating Margin
CNTB
CNTB
PDLB
PDLB
Q4 25
43.6%
Q3 25
32.8%
Q2 25
30.2%
Q1 25
32.5%
Q4 24
19.6%
Q3 24
15.2%
Q2 24
56.6%
21.8%
Q1 24
18.3%
Net Margin
CNTB
CNTB
PDLB
PDLB
Q4 25
36.3%
Q3 25
24.3%
Q2 25
23.0%
Q1 25
24.2%
Q4 24
14.1%
Q3 24
12.1%
Q2 24
61.6%
15.8%
Q1 24
11.8%
EPS (diluted)
CNTB
CNTB
PDLB
PDLB
Q4 25
$0.43
Q3 25
$0.27
Q2 25
$0.25
Q1 25
$0.25
Q4 24
$0.11
Q3 24
$0.10
Q2 24
$0.27
$0.14
Q1 24
$0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNTB
CNTB
PDLB
PDLB
Cash + ST InvestmentsLiquidity on hand
$110.2M
$126.2M
Total DebtLower is stronger
$596.1M
Stockholders' EquityBook value
$110.9M
$541.5M
Total Assets
$120.6M
$3.2B
Debt / EquityLower = less leverage
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNTB
CNTB
PDLB
PDLB
Q4 25
$126.2M
Q3 25
$146.6M
Q2 25
$126.6M
Q1 25
$129.9M
Q4 24
$139.8M
Q3 24
$155.8M
Q2 24
$110.2M
$103.2M
Q1 24
$134.7M
Total Debt
CNTB
CNTB
PDLB
PDLB
Q4 25
$596.1M
Q3 25
$521.1M
Q2 25
$536.1M
Q1 25
$521.1M
Q4 24
$596.1M
Q3 24
$580.4M
Q2 24
$680.4M
Q1 24
$680.4M
Stockholders' Equity
CNTB
CNTB
PDLB
PDLB
Q4 25
$541.5M
Q3 25
$529.8M
Q2 25
$521.1M
Q1 25
$513.9M
Q4 24
$505.5M
Q3 24
$504.6M
Q2 24
$110.9M
$497.7M
Q1 24
$493.7M
Total Assets
CNTB
CNTB
PDLB
PDLB
Q4 25
$3.2B
Q3 25
$3.2B
Q2 25
$3.2B
Q1 25
$3.1B
Q4 24
$3.0B
Q3 24
$3.0B
Q2 24
$120.6M
$2.8B
Q1 24
$2.8B
Debt / Equity
CNTB
CNTB
PDLB
PDLB
Q4 25
1.10×
Q3 25
0.98×
Q2 25
1.03×
Q1 25
1.01×
Q4 24
1.18×
Q3 24
1.15×
Q2 24
1.37×
Q1 24
1.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNTB
CNTB
PDLB
PDLB
Operating Cash FlowLast quarter
$-8.0M
$55.6M
Free Cash FlowOCF − Capex
$54.6M
FCF MarginFCF / Revenue
173.9%
Capex IntensityCapex / Revenue
3.1%
Cash ConversionOCF / Net Profit
-0.54×
5.48×
TTM Free Cash FlowTrailing 4 quarters
$74.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNTB
CNTB
PDLB
PDLB
Q4 25
$55.6M
Q3 25
$1.4M
Q2 25
$6.2M
Q1 25
$13.1M
Q4 24
$7.2M
Q3 24
$-14.6M
Q2 24
$-8.0M
$-2.6M
Q1 24
$1.5M
Free Cash Flow
CNTB
CNTB
PDLB
PDLB
Q4 25
$54.6M
Q3 25
$786.0K
Q2 25
$5.9M
Q1 25
$12.9M
Q4 24
$4.5M
Q3 24
$-15.0M
Q2 24
$-2.6M
Q1 24
$-315.0K
FCF Margin
CNTB
CNTB
PDLB
PDLB
Q4 25
173.9%
Q3 25
2.9%
Q2 25
22.4%
Q1 25
52.6%
Q4 24
19.7%
Q3 24
-74.1%
Q2 24
-13.0%
Q1 24
-1.5%
Capex Intensity
CNTB
CNTB
PDLB
PDLB
Q4 25
3.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
11.9%
Q3 24
2.0%
Q2 24
0.3%
Q1 24
8.7%
Cash Conversion
CNTB
CNTB
PDLB
PDLB
Q4 25
5.48×
Q3 25
0.21×
Q2 25
1.01×
Q1 25
2.20×
Q4 24
2.46×
Q3 24
-5.99×
Q2 24
-0.54×
-0.80×
Q1 24
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons